MedTrace Logo

Social Media Posts About Cancer: Five Timepoints

NCT07588607 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2026-05-15

No results posted yet for this study

Summary

The main purpose of this trial was to evaluate the impact of user interface designs on intervening with cancer misinformation on social media. The investigators conducted a randomized clinical trial with a sample of 294 US adults (ages 18-65) who previously had a cancer diagnosis or were a cancer caregiver. This registration record only covers the 5 timepoint trial under the same IRB number.

Conditions

Interventions

BEHAVIORAL

Social cue prompt and policy

Cancer misinformation posts are shown with a prompt above the post caption that read, "This post has been flagged as false and potentially harmful by \[47 or 48\] people on Invibe. If you want to report, click the flag below." The social media launch screen had an overlaid policy for removing flagged posts: "We are committed to working with you and others on Invibe to reduce false and potentially harmful information. When a post is flagged by 50 people, we remove it until we verify the information. Please help us make the Invibe experience a good one for all."

BEHAVIORAL

Standard prompts

Cancer misinformation posts are shown with a prompt above the post caption that read, "This post has been flagged as false and potentially harmful. If you want to report, click the flag below."

Sponsors & Collaborators

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Allison J Lazard, PhD · UNC Lineberger Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2025-05-12
Completion
2025-05-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07588607 on ClinicalTrials.gov